BCMA-Binding Monoclonal Antibody CDR3 Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel antibodies that specifically bind to BCMA with high affinity for therapeutic applications in diseases such as leukemia, lymphoma, or multiple myeloma, as existing anti-BCMA antibodies are limited.
Innovation Solution
Development of monoclonal antibodies and antigen-binding fragments that specifically bind to BCMA with high affinity, characterized by specific CDR sequences in their variable domains, including various subclasses and isotypes, and optimized for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing anti-BCMA antibodies are used, then therapeutic applications are limited, but developing novel antibodies requires significant research and development resources
Solution Approach 1:
The patent applies parameter changes by systematically varying the CDR3 region sequences while maintaining conserved CDR1 and CDR2 regions. This approach generates multiple antibody variants with different binding affinities and specificities to BCMA, enabling broader therapeutic applications without completely redesigning the antibody structure. The method transforms a single antibody into a family of related antibodies with optimized properties for different therapeutic indications.
2Reliability
If high binding affinity to BCMA is achieved, then therapeutic efficacy is enhanced, but specificity may be compromised
Solution Approach 1:
The patent applies local quality by making targeted modifications specifically to the CDR3 region while keeping CDR1 and CDR2 regions conserved. This localized approach allows optimization of binding affinity through CDR3 variations without disrupting the overall specificity determined by the framework regions and conserved CDR elements. Each antibody variant maintains the core specificity profile while achieving enhanced affinity through local sequence optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed antibodies exhibit high binding affinity and specificity to BCMA, potentially enhancing therapeutic efficacy in treating BCMA-mediated diseases.
Implementation Method 1
a monoclonal antibody or antigen-binding fragment thereof that specifically binds to BCMA... characterized in that the variable domain of the heavy chain comprises: CDR1 with the amino acid sequence SX1X2MS... CDR2 with the amino acid sequence X3YNGGSDRAGX4X5DSVX6G
Data Source
AI summary
The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to BCMA. The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods for treating BCMA-mediated diseases or disorders, uses of the antibodies or pharmaceutical compositions thereof for treating BCMA-mediated diseases or disorders, and uses of the antibodies and other therapeutically active compounds for treating BCMA-mediated diseases or disorders.